Dicerna Pharmaceuticals, Inc.
If you purchased Dicerna Pharmaceuticals, Inc. securities and would like to join the action, please click "Join This Action" below.
DICERNA MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF DICERNA PHARMACEUTICALS, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – DRNA
November 18, 2021.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) to Novo Nordisk for $38.25 per share in cash is fair to Dicerna shareholders.
The investigation concerns whether Dicerna and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Dicerna shareholders; (2) determine whether Novo Nordisk is underpaying for Dicerna; and (3) disclose all material information necessary for Dicerna shareholders to adequately assess and value the merger consideration. On behalf of Dicerna shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.